COMPARE CHARACTERISTIC OF CLINICAL STATE AND INDEX OF LIPID SPECTRUM DYNAMICS IN PATIENTS WITHOUT AND AFTER AORTIC-CORONARY BYPASS DURING THE STAGES OF ATORVASTATIN THERAPY

  • O.О. Gunaeva-Kruchina
Keywords: chronic ishemic heart disease, atorvastatin, lipid spectrum, clinical state, dislipoproteide-mia

Abstract

During the investigation 40 out – patients with chronic ischemic heart disease (CIHD) 18 – without 22 – after aortic–coronary bypass (acb) were observed. The average period of time after operation before initial investigation comprised (1±3, 5) years. Patients were divided into 2 groups according to the types of dislipoproteidemia. 10 patients without асb has 2a type of dislipoproteidemia, 8 – 2b type, 15 patients after aortic–coronary bypass – 2a type, 7 – 2b type. Аll patients received atorvastatin 10 mg. Dynamics of clinical state evaluates by patient complaints of dispnea, angina pectoralis and stability of physical loards. Total cholesterol, LDL, VLDL, HDL, triglycerides, index of atherogenity were evaluated ones at 3 months. During the therapy the optimization index of lipid spectrum and clinical state indices was noted in all patients, without regarding aortic coronary bypass and grade of dislipoproteidemia. Durig the investigation after 3 months it came the decrease of lipid level and angina pectoralis attack, increase stability of physical loards.

Downloads

Download data is not yet available.

References

1. Арутюнов Г.П. // Клиническая фармакология и терапия. - 2001 - № 10 (3). - С. 2-8.

2. Alaupovic P., Heinonen, T. Shurzinske L., at al. // Atherosclerosis. - 1997. - Vol.133. - P. 123-133.

3. Aikawa M., Libby P. // Cardiovascular Risk Factor. - 2000. - № 9. - Р. 183-194.

4. Alaupovic P., Heinonen, T. Shurzinske L., at al. // Atherosclerosis. – 1997. - № 133. - Р. 123-133.

5. Amoroso G., Van Boven A.J., Crijns H.S. // Am. Heart J. - 2001. - № 141. - Р. 22-25.

6. Athyros V.G., Papageorgiou A.A., Dimokritos S. at al. // Curr. Med. Res. Opin. - 2001. - № 17 (4). - Р. 267-272.

7. Athyros V.G., Papageorgiou A.A., Hatzikonstantinou H.A. at al. // Clin. Drug. Invest. - 1998. - № 16. - Р. 219-227.

8. Aikawa M., Libby P. // Cardiovascular Risk Factor. - 2000. - № 9. - Р. 183-194.

9. Грацианский Н.А. // Кардиология. - 1998. - № 38 (3). - С. 75-78.

10. Лутай М.И. // Нова медицина. - 2005. - № 3(20). - С. 5-10.

11. Яблучанский Н.И. // Медицинская газета «Medicus Amicus». - 2002. - № 1. - С. 1-3.

12. Fox KF, Cowie M-R-, Wood D-A., et al. // Eur Heart J. - 1999. - № 20(4). - Р. 256-262.

13. Cowie MR, Mosterd A, Wood DA, et al. // Eur Heart J. - 1997. - № 18(2). – Р. 208-225.

14. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.// Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial. JAMA. - 2001.- № 285. - Р. 1711-1718.
How to Cite
Gunaeva-Kruchina, O. (1). COMPARE CHARACTERISTIC OF CLINICAL STATE AND INDEX OF LIPID SPECTRUM DYNAMICS IN PATIENTS WITHOUT AND AFTER AORTIC-CORONARY BYPASS DURING THE STAGES OF ATORVASTATIN THERAPY. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine", (13), 83-88. Retrieved from https://periodicals.karazin.ua/medicine/article/view/7085
Section
Clinical research